Abstract
The present study investigated the potential difference between EGFR-mutated lung adenocarcinoma (ADC) and KRAS-mutated ADC in relation to past illness and family history. Among the 153 tumors examined, 33 (21.6%) were EGFR-mutated, and 22 (14.4%) were KRAS-mutated. The EGFR-mutated cases showed a significantly higher prevalence of past illness involving the gastric cancer in males (EGFR 3/8 (37.5%), KRAS 0/13 (0.0%), no mutation (NONE) 1/57 (1.8%); Fisher's exact test, P=0.0064) or uterine myoma in females (EGFR 8/25 (32.0%), KRAS 0/9 (0.0%), NONE 3/41 (7.3%); Fisher's exact test, P=0.0139). No association between the mutations and family history was found. The EGFR-mutated ADC is therefore likely to develop through a distinct carcinogenetic pathway from the others, but genetic backgrounds seemed unlikely to be determinant predisposing to the EGFR-mutated ADC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / epidemiology
-
Adenocarcinoma / genetics*
-
Adenocarcinoma / pathology
-
Age Factors
-
DNA Mutational Analysis
-
Female
-
Genes, erbB-1 / genetics*
-
Genetic Association Studies
-
Humans
-
Lung Neoplasms / epidemiology
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / pathology
-
Male
-
Mutation
-
Myoma / epidemiology
-
Myoma / genetics*
-
Myoma / pathology*
-
Neoplasms, Second Primary / genetics*
-
Neoplasms, Second Primary / pathology
-
Prevalence
-
Proto-Oncogene Proteins / genetics*
-
Proto-Oncogene Proteins p21(ras)
-
Risk Factors
-
Smoking
-
Stomach Neoplasms / epidemiology
-
Stomach Neoplasms / genetics*
-
Stomach Neoplasms / pathology*
-
Uterine Neoplasms / epidemiology
-
Uterine Neoplasms / genetics*
-
Uterine Neoplasms / pathology*
-
ras Proteins / genetics*
Substances
-
KRAS protein, human
-
Proto-Oncogene Proteins
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins